Key findings include: Personalized whole-genome sequencing (WGS) panels utilizing up to 1,000 somatic variants were successfully created via Precise MRD for 97.3% of patients tested. Precise MRD ...

Myriad Genetics, Inc. MYGN recently announced an agreement with Personalis, Inc. to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD).

The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN’s reach in MRD testing and cover solid tumors and hematological cancers. Minimal residual disease (MRD ...

(RTTNews) - Natera, Inc. (NTRA), a leader in cell-free DNA and precision medicine, announced that its genome-based Signatera MRD assay has secured Medicare coverage under LCD L38779. This coverage ...

5 sensitivity. Over 50 percent of patients achieved sustained MRD negativity for at least 24 months, and more than two-thirds maintained MRD negativity at 12 months. This translated to a ...